

Original research

Open Access

The effect of CpG-ODN on antigen presenting cells of the foal

M Julia BF Flaminio*¹, Alexandre S Borges², Daryl V Nydam³,
David W Horohov⁴, Rolf Hecker⁵ and Mary Beth Matychak¹

Address: ¹Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA, ²Departamento de Clinica Veterinaria, Faculdade de Medicina Veterinaria e Zootecnia, Universidade Estadual Paulista 'Julio de Mesquita Filho', UNESP-Campus de Botucatu, SP, Brazil, ³Department of Population Medicine and Diagnostics Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA, ⁴Department of Veterinary Science, Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY, USA and ⁵Qiagen GmbH, Hilden, Germany; current address Tübingen, Germany

Email: M Julia BF Flaminio* - mbf6@cornell.edu; Alexandre S Borges - asborges@fmvz.unesp.br; Daryl V Nydam - dvn2@cornell.edu; David W Horohov - David.Horohov@uky.edu; Rolf Hecker - rolf.hecker@gmx.com; Mary Beth Matychak - mbm10@cornell.edu

* Corresponding author

Published: 25 January 2007

Received: 12 October 2006

Accepted: 25 January 2007

Journal of Immune Based Therapies and Vaccines 2007, **5**:1 doi:10.1186/1476-8518-5-1

This article is available from: <http://www.jibtherapies.com/content/5/1/1>

© 2007 Flaminio et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Cytosine-phosphate-guanosine oligodeoxynucleotide (CpG-ODN) has been used successfully to induce immune responses against viral and intracellular organisms in mammals. The main objective of this study was to test the effect of CpG-ODN on antigen presenting cells of young foals.

Methods: Peripheral blood monocytes of foals (n = 7) were isolated in the first day of life and monthly thereafter up to 3 months of life. Adult horse (n = 7) monocytes were isolated and tested once for comparison. Isolated monocytes were stimulated with IL-4 and GM-CSF (to obtain dendritic cells, DC) or not stimulated (to obtain macrophages). Macrophages and DCs were stimulated for 14–16 hours with either CpG-ODN, LPS or not stimulated. The stimulated and non-stimulated cells were tested for cell surface markers (CD86 and MHC class II) using flow cytometry, mRNA expression of cytokines (IL-12, IFN α , IL-10) and TLR-9 using real time quantitative RT-PCR, and for the activation of the transcription factor NF- κ B p65 using a chemiluminescence assay.

Results: The median fluorescence of the MHC class II molecule in non-stimulated foal macrophages and DCs at birth were 12.5 times and 11.2 times inferior, respectively, than adult horse cells (p = 0.009). That difference subsided at 3 months of life (p = 0.3). The expression of the CD86 co-stimulatory molecule was comparable in adult horse and foal macrophages and DCs, independent of treatment. CpG-ODN stimulation induced IL-12p40 (53 times) and IFN α (23 times) mRNA expression in CpG-ODN-treated adult horse DCs (p = 0.078), but not macrophages, in comparison to non-stimulated cells. In contrast, foal APCs did not respond to CpG-ODN stimulation with increased cytokine mRNA expression up to 3 months of age. TLR-9 mRNA expression and NF- κ B activation (NF- κ B p65) in foal DCs and macrophages were comparable (p > 0.05) to adult horse cells.

Conclusion: CpG-ODN treatment did not induce specific maturation and cytokine expression in foal macrophages and DCs. Nevertheless, adult horse DCs, but not macrophages, increased their expression of IL-12 and IFN α cytokines upon CpG-ODN stimulation. Importantly, foals presented an age-dependent limitation in the expression of MHC class II in macrophages and DCs, independent of treatment.

Background

The susceptibility of the naïve foal to infection in the neonatal period is greatly dependent on the adequacy of transfer and absorption of maternally-derived antibodies through the colostrum. Passively-transferred humoral immune protection, though, is limited and short-lived. When maternal antibodies are reduced to low levels, the foal must rely on its immune system to resist infections. In addition, protection against intracellular pathogens may require cellular immunity. Therefore, early maturation of the foal's immune system would likely increase resistance to infectious disease.

Bacterial DNA has a potent immunostimulatory activity explained by the presence of frequent unmethylated cytosine-phosphate-guanosine (CpG) motifs [1,2]. Synthetic CpG-oligodeoxynucleotides (CpG-ODN) have shown potent immunostimulatory activity in adult and in neonatal vertebrates likely because they mimic bacterial DNA [3]. *In vivo*, CpG-ODNs have been shown to induce strong Type 1 immune responses, with subsequent activation of cellular (cytotoxic T lymphocytes, CTLs) and humoral (Th1 immunoglobulin isotypes) components [4]. Therefore, CpG-ODNs have been extensively studied for their application as adjuvants in vaccines in domestic species, including bovine, ovine and swine, revealing increase in vaccine efficacy and protection [5-11]. In the horse, CpG-ODN 2007 formulated in 30% Emulsigen added to a commercial killed-virus vaccine against equine influenza virus enhanced the antibody responses in comparison to the vaccine alone [12].

Toll-like receptors (TLRs) are essential for the recognition of highly conserved structural motifs (pathogen-associated molecular patterns or PAMPs) only expressed by microbial pathogens. The combination of different TLRs provides detection of a wide spectrum of microbial molecules. For instance, TLR-4 specifically recognizes lipopolysaccharide (LPS) derived from gram-negative bacteria, whereas bacterial DNA (unmethylated CpG motif) is recognized by TLR-9 [13]. TLRs are predominantly expressed on antigen-presenting cells [macrophages, dendritic cells (DCs) and, to some extent, B cells], which are abundantly present in immune tissues (spleen, lymph nodes, peripheral blood leukocytes), as well as tissues that are directly exposed to microorganisms (lungs, gastrointestinal tract, skin). The nuclear-factor κ B (NF- κ B) is a transcription factor activated upon recruitment of the adaptor MyD88 and TLR 4 or TLR9 engagement with PAMPs [14]. Antigen presenting cells (APCs) play a major role in the initiation and instruction of antigen-specific immune response, and are the link between innate and adaptive immunity: they recognize, process and present antigen to T cells. Many studies have indicated that DCs, but not macrophages, are critical for the induction of primary immune responses,

i.e. a first time T cell encounter with processed antigen [15]. Dendritic cells ability to process and present antigen depends on their stage of maturation, and circulating precursor DCs enter tissues as immature DCs. After antigen capture, they migrate to secondary lymphoid organs where they become mature DCs. Immature DCs exhibit active phagocytosis but lack sufficient cell surface MHC class II and co-stimulatory molecules (CD83, CD86) for efficient antigen presentation to T lymphocytes [16]. In contrast, mature DCs demonstrate decreased capacity of phagocytosis and antigen processing, and increased expression of MHC class II and co-stimulatory molecule on the cell surface. CpG-ODNs have been shown to induce maturation of DCs by increasing cell surface expression of MHC class II, CD40, and CD86/80 molecules [17]. In combination with antigens, CpG-ODNs enhance antigen processing and presentation by DCs and the expression of Type I cytokines (i.e. type I interferon IFN α and IL-12) [18]. In the horse, Wattrang et al. (2005) demonstrated that phosphodiester ODN containing unmethylated CpG-ODN motif induced type I interferon production in peripheral blood mononuclear cells [19]. Activation of human monocytes through Toll-like receptor has been shown to induce their differentiation into either macrophages or DCs, and the presence of GM-CSF is synergistic for the expression of MHC class II, CD86, CD40 and CD83 molecules, mixed lymphocyte reaction and the secretion of Th1 cytokines by T cells [20].

In contrast to adults, human neonates have demonstrated impaired response to multiple PAMPs, which may significantly contribute to immature neonatal immunity [21,22]. Nevertheless, CpG-ODN has been shown to induce *in vitro* IFN α cytokine production and reduce *in vivo* viral shedding in newborn lambs [23]. To date, limited information is available about the competence of foal cells to detect pathogens and trigger an immune response against them. A similar dependency in APC competency could exist in the foal in regards to resistance to viral and intracellular bacterial infections, for instance *Rhodococcus equi*, which causes pyogranulomatous pneumonia exclusively in young foals [24,25].

The *ex vivo* system used in this investigation allowed a longitudinal study of the immune cells of the foal. We investigated the effect of a CpG-ODN on monocyte-derived macrophages and DCs from adult horses and foals from birth to 3 months of life. We evaluated the effect of CpG-ODN in the maturation process of dendritic cells of foals and compared to those of adult horses by measuring cell surface molecule expression, cytokine profile, and signaling pathway activation.

Methods

Foals, adult horses and blood samples

This study was conducted following a protocol approved by Cornell University Center for Animal Resources and Education and the guidelines from the Institutional Animal Care and Use Committees. Eight pregnant mares of various breeds (1 Bavarian, 1 Westfalen, 1 Selle Fraincaise, 1 Thoroughbred, 2 Oldenburg, 2 Pony mares) belonging to the Cornell University Equine Park were monitored for this study. Those mares had access to pasture and barn, and they were fed grass hay and grain according to their management schedule. They were vaccinated approximately 30 days before foaling with Encevac-T® (Intervet, DeSoto, KS). All the foalings were observed, and the adequate absorption of colostral immunoglobulin G (IgG) by the foals was assessed using the SNAP® Test (Idexx, Westbrook, MN) by 18 hours of birth. Daily physical examination in the first week of life, and monthly complete blood cell count were performed to evaluate natural inflammatory/infectious conditions in the foals.

Sixty milliliter peripheral blood samples were collected from the 8 foals via jugular venipuncture using heparinized vacutainer tubes within 5 days of life, and monthly up to 3 months of life. One of the foals was euthanized due to septic synovitis and was removed from the study. An equivalent amount of blood was collected once from 7 different adult horses (5 Thoroughbred and 2 ponies). All the samples were processed as below immediately after collection.

Monocyte-derived macrophages and dendritic cells

Monocytes were purified from peripheral blood using a modified technique described by Hammond et al. [26]. Briefly, mononuclear cells were isolated using Ficoll-Paque (Amershan Biosciences, Piscataway, NJ) density centrifugation, and incubated in DMEM-F12 medium (Gibco-Invitrogen Corporation, Grand Island, NY) plus 5% bovine growth serum (Hyclone, Logan UT), antibiotics and antimycotics (Gibco-Invitrogen Corporation, Grand Island, NY) for 4 h at 5% CO₂, 37°C. All those reagents were certified for the presence of lipopolysaccharide. The loosely adherent and non-adherent cells were removed by gentle wash with 37°C phosphate buffered solution (PBS). For the generation of DCs, recombinant equine IL-4 (rEqIL-4, 10 ng/ml) and recombinant human granulocyte-monocyte colony stimulating factor (rHuGM-CSF, 1000 units/ml, R&D Systems, Minneapolis, MN) were added to the culture medium as the following:

Dendritic cell baseline control: for the generation of DCs, monocytes were cultured in the presence of rEqIL-4 and rHuGM-CSF for 5 days.

To test the effect of CpG-ODN or LPS on dendritic cells: monocytes were cultured in the presence of rEqIL-4 (10 ng/ml) and rHuGM-CSF (1,000 units/ml) for 5 days, followed by the addition of CpG-ODN 1235 (10 µg/ml, Qiagen, Hilden, Germany) or LPS (Sigma Diagnostics, Inc., St. Lois, MO) to the medium for 14–16 hours.

Macrophage baseline control: monocytes were cultured with no extra additives for 5 days.

To test the effect of CpG-ODN or LPS on macrophages: monocytes were cultured with no extra additives for 5 days, followed by the addition of CpG-ODN 2135 (10 µg/ml) or LPS (12.5 µg/ml) to the medium for 14–16 hours.

Cell viability (> 90%) and morphology (formation of dendrites) were tested by 0.2% Trypan blue (Gibco BRL, Grand Island, NY) exclusion and contrast phase microscopy, respectively. One portion of the cultured cells was tested for cell surface molecule expression using flow cytometry. The adhered cells were detached from the wells using 5 mM EDTA in medium for 5–10 minutes at 37°C, and washed with fresh PBS. The plates were evaluated afterward to ensure all cells were removed for analysis. In general, macrophages presented moderate adherence to the plates, whereas dendritic cells were loose or loosely attached. The other portion was snap frozen in liquid nitrogen and stored at minus 80°C for: a) RNA extraction, and subsequent measurement of gene expression using real-time RT-PCR; or b) measurement of NF-κB activation using a chemiluminescence assay.

Unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides (CpG-ODN) motifs

In this study, we used the synthetic CpG-ODN 2135 (TCGTCGTTTGTGCGTTTGTGCGTT) (Merial, USA), which has been shown to induce equine peripheral blood mononuclear cell proliferation *in vitro* [27]. To confirm the recognition of this CpG-ODN motif by horse peripheral blood leukocytes and collect preliminary data about the response in foals, 2-day-old foal (n = 5) and adult horse (n = 5) isolated peripheral blood mononuclear cells, and a 5-day-old foal isolated mesenteric lymph node mononuclear cells (n = 1) were cultured in the presence or absence of 5 µg/ml or 10 µg/ml CpG-ODN 2135, 12.5 µg/ml LPS or non-stimulated. Approximately 4 × 10⁵ cells/well were cultured in a 96-well plate and medium described above. The cells were incubated for 3 days at 37°C in 5% CO₂, and pulsed with 0.8 µCi [³H]-thymidine per well for the last 8 hours of incubation. Well contents were harvested onto glass fiber filters and [³H]-thymidine incorporation was measured using a liquid scintillation beta counter. The stimulation index was calculated dividing the average counts per minute from stimulated cells by the average counts per minute from non-stimulated cells.

Flow cytometric analysis of cell surface markers

Cell surface markers of monocyte-derived macrophages and DCs were evaluated by flow cytometry after 5 days of culture (Day 5) and after overnight stimulation with CpG-ODN or LPS (Day 6). The assay was performed according to Flaminio et al. [28], and monoclonal antibodies used are described in Table 1 [29-31]. Leukocyte subpopulations were displayed in a dot plot and gated according to size based on forward light scatter (FSC), and according to granularity based on 90 degree side light scatter (SSC). The cell population of interest was gated away from small and dead cells, including events greater than 400 FSC and 200 SSC. Both percentage positive cells and mean fluorescence expression were measured.

Real-time RT-PCR reactions for cytokine mRNA expression

Quantitative analysis of cytokine mRNA expression was performed as described in Flaminio et al. [32]. Isolation of total RNA from monocyte-derived macrophages and DCs was performed using RNeasy[®] Mini Kit (Qiagen, Valencia, CA), and quality of RNA was tested by 260/280 nm. The RNA product was treated with DNase to eliminate possible genomic DNA from the samples, and the lack of amplification of genes in samples without the addition of reverse transcriptase confirmed the purity of RNA. A same amount (0.01 µg in 1 µL) of RNA from each sample was used to test for the expression of cytokines. The cytokine (IL-10, IL-12p35, IL-12p40 and IFN α) and Toll-like receptor 9 (TLR9) gene expression in stimulated and non-stimulated cells was measured in triplicate using Taqman[®] one-step RT-PCR master mix reagents, specific primers and probes designed using published equine sequences (Table 2), and the ABI Prism[®] 7700 Sequence Detection System (AB Biosystems, Foster City, CA). In a small subset of adult horse cells (n = 3), the expression of TNF α mRNA was tested at 14–16 hours of culture. Analysis of data was performed by normalizing the target gene amplification value (Target C_T) with its corresponding endogenous control (β actin, Reference C_T). The quantity of the target gene in each sample was calculated relatively to the calibrator sample (fold difference over Day 5 non-stimulated cells).

To determine the time-point for cell harvesting that corresponded to the approximate peak of cytokine expression in CpG-ODN stimulated cells, samples from 3 adult horses were tested at different time points for cytokine mRNA expression. Results indicated that the peak of IL-12p40 expression was observed between 12 and 24 hours of stimulation (data not shown).

Toll-like receptor 9 (TLR9)

Consensus sequence was obtained by aligning the human, bovine, ovine, canine, feline and murine TLR9 gene sequences using the gene alignment NTI software.

Primers for the consensus sequence were designed and used for PCR amplification of horse cDNA obtained from purified peripheral blood leukocyte RNA. Gel electrophoresis of the PCR product using low melting point gel agar revealed a single band of expected size. The PCR product was purified using QIAquick PCR purification kit (Qiagen, Valencia, CA). The PCR product was ligated into the pDrive cloning vector, followed by transformation of Quiagen EZ chemically competent cells (Qiagen, Valencia, CA). Selected colonies were grown overnight and plasmid DNA was isolated with the QIAprep Spin Miniprep Kit (Qiagen, Valencia, CA). Inserts were confirmed with restriction digest and/or PCR. Desired clones were sequenced with universal primers at Cornell University Sequencing Center. Primers and probes were designed for the quantitative RT-PCR using the equine sequence and the PrimerExpress software (ABIPrism). The equine TLR9 partial sequence was submitted to GenBank under accession number [DQ157779](http://www.ncbi.nlm.nih.gov/nucl/157779).

Nuclear-factor kappa B (NF-kB)

The activation of NF-kB was measured using the commercially available chemiluminescent TransAM[™] NF-kB transcription factor kit that measures the NF-kB p65 subunit (Active Motif, Carlsbad, CA). The kit contains a 96-well plate coated with oligonucleotide containing a NF-kB consensus site (5'-GGGACTTTC-3'). Only the active form of NF-kB (i.e. not bound to inhibitor I κ B) specifically binds to this oligonucleotide. Therefore, nuclear purification is not necessary for this assay because inactivated cytoplasmic NF-kB cannot bind to the immobilized sequence. A primary antibody that recognizes the p65 subunit epitope is used subsequently to the incubation with cellular extract, which is obtained using the buffers included in the kit. A horse-radish-peroxidase-conjugated secondary antibody is used for the chemiluminescence assay. A standard curve was generated using dilutions of the NF-kB standard protein (Active Motif, Carlsbad, CA). Results were expressed in ng/µL.

Statistical Analysis

Descriptive statistics were generated and distributions of data were analyzed using commercial software (PROC Univariate, SAS Institute, Version 9.1, Cary, NC). Box and Whiskers plots were produced using commercial software (KaleidaGraph, Version 4.01, Synergy Software, Reading, PA). Box plots represent the data collected. The box includes 50% of the observations with the top line indicating the upper quartile, the middle line showing the median value, and the lower line indicating the lower quartile. The lines extending from the box ("whiskers") mark the maximum and minimal values observed that are not outliers. Outliers are depicted by circles are a values that are either greater than the upper quartile + 1.5* the interquartile distance (ICD) or less than the lower quartile

Table 1: Monoclonal antibodies used to test the expression of cell surface markers of monocyte-derived macrophages and dendritic cells stimulated or not with CpG-ODN or LPS

MARKER	ANTIBODY	CLONE	SUPPLIER	VALIDATION
CD172a	mouse anti-bovine CD172a	DH59B	VMRD, Pullman, WA	Kydd et al., 1994
CD86	mouse anti-human CD86	2331(FUN-1)	Becton and Dickinson, San Diego, CA	Hammond et al., 1999
MHC I	mouse anti-horse MHC I	CZ3	D. Antczak's laboratory, Cornell University	Lunn et al., 1998
MHC II	mouse anti-horse MHC II	CZ11	D. Antczak's laboratory, Cornell University	Lunn et al., 1998
CD14	mouse anti-human CD14	big10	Biometec, Germany	Steinbach et al., 1998
Negative	mouse anti-canine parvovirus	--	C.Parrish's laboratory, Cornell University	Parrish et al., 1982

- 1.5*ICD. Non-normally distributed data was analyzed using non-parametric techniques (i.e. Kruskal-Wallis and Wilcoxin rank-sum, or Wilcoxin signed-rank depending on the number of comparisons and/or independence of observations) performed by commercially available soft-

ware (PROC Npar1way, SAS Institute, Version 9.1, Cary, NC). General linear regression was used to examine the association between cell surface marker expression and age (PROC Reg, SAS Institute, Version 9.1, Cary, NC). The level of significance was set at $p < 0.05$.

Table 2: Primer and probe sequences used to measure mRNA expression in monocyte-derived macrophages and dendritic cells

CYTOKINE	PRIMER AND PROBE SEQUENCES	GenBank accession #
IL-12p35	5'-TCA AGC TCT GCA TCC TTC TTC AT-3' 5'-CAG ATA GCC CAT CAT CCT GTT G-3' 5'-FAM-CCT TCA GAA TCC GCG CAG TGA CCA-TAMRA-3'	Y11130
IL-12p40	5'-CAC CTG CAA TAC CCC TGA AGA-3' 5'-TGC CAG AGC CTA AGA CCT CAT T-3' 5'-FAM-CAT CAC CTG GAC CTC GGC CCA-TAMRA-3'	Y11129
IFNα	5'-AGG TGT TTG ACG GCA ACC A-3' 5'-ACG AGC CGT CTG TGC TGA A-3' 5'-FAM-AGC CTC AAG CCA TCT CCG CGG T-TAMRA-3'	M14540
IL-10	5'-GAC ATC AAG GAG CAC GTG AAC TC-3' 5'-CAG GGC AGA AAT CGA TGA CA-3' 5'-FAM-AGC CTC ACT CGG AGG GTC TTC AGC TT-TAMRA-3'	U38200
TNFα	5'-GAT GAC TTG CTC TGA TGC TAA TCC-3' 5'-TCT GGG CCA GAG GGT TGA T-3' 5'-FAM-TCT CCC CAG CAG TTA CCG AAT GCC TT-TAMRA-3'	M64087
TLR9	5'-AAC TGG CTG TTC CTG AAG TCT GTG-3' 5'-TCA ACC TCA AGT GGA ACT GCC C-3' 5'-FAM-AGA GAA CTG TCC TTC AAC ACC AGG-TAMRA-3'	DQ157779
β-actin	5'-TCA CGG AGC GTG GCT ACA-3' 5'-CCT TGA TGT CAC GCA CGA TTT-3' 5'-FAM-CAC CAC CAC GGC CGA-TAMRA-3'	AF035774

Results

Effect of CpG-ODN 2135 in peripheral blood mononuclear cells of foals and adult horses

In a pilot study, we tested the proliferative response of 2-day-old foal (n = 5) and adult horse (n = 5) isolated peripheral blood mononuclear cells, and a 5-day-old foal isolated mesenteric lymph node mononuclear cells (n = 1) to CpG-ODN 2135 or non-stimulation. Those leukocytes included B cells and monocytes, which potentially express TLR9 and respond to CpG-ODN stimulation. Our results indicated that CpG-ODN 2135 motif induced proliferation of foal lymph node leukocytes *in vitro* with median stimulation indexes equal to 2 and 3 when cells were stimulated with 5 µg/ml or 10 µg/ml CpG-ODN 2135 final concentration, respectively, versus median stimulation index 0.8 when cells were stimulated with 12.5 µg/ml LPS. In addition, foal peripheral blood mononuclear cells responded to 10 µg/ml CpG-ODN or 12.5 µg/ml LPS with cell proliferation median stimulation indexes equal to 1.2 and 2.5, respectively. Adult horse cells presented median stimulation indexes 7.3 and 16.3, respectively.

Cell culture system

Our *ex vivo* propagated adult horse monocyte-derived macrophages and DCs on Day 5 of culture exhibited a similar surface antigen phenotype to the one described by Hammond et al. [26] and Mauel et al. [33]. On day 5 of culture, adult horse and foal macrophages appeared round and attached to the plastic bottom of the culture plate (Figure 1). Foal macrophages tended to become giant cells more frequently in 2–3 month-old foal samples. In contrast, the adult horse and foal dendritic cells were elongated. After stimulation (day 6), occasional dendritic cells with stellate shape were observed, whereas many cells detached from the plastic, isolated or forming clumps, but keeping the dendrites.

Approximately 30% and 19% of the monocyte-derived macrophages and DCs, respectively, expressed the CD14 marker. Approximately 61% and 77% of the monocyte-derived macrophages and DCs, respectively, expressed the CD172a marker. Overall, non-stimulated dendritic cells expressed 1.4 and 1.2 times median fluorescence intensity (hence molecular expression) for MHC class II and CD86, respectively, than macrophages (Figure 2). The percentages of CD8+ or CD4+ in rEqIL-4+rHuGM-CSF-stimulated cells were less than 3% and 9%, respectively. Foal cells presented similar phenotype to adult horse cells.

Cell surface marker expression in stimulated and non-stimulated cells

Median fluorescence intensity of MHC class II expression was greater but not statistically significant different ($p > 0.05$) in DCs than in macrophages of adult horses and

foals (Figure 3). Although there was no specific effect of CpG-ODN stimulation in adult horse and foal cells, there was an age-dependent limitation in the expression of MHC class II (fluorescence) on both macrophage and DCs of foals ($p < 0.035$). The median fluorescence of the MHC class II molecule in non-stimulated foal macrophages and DCs at birth were 12.5 times ($p = 0.009$) and 11.2 times ($p = 0.009$) inferior, respectively, to adult horse cells. At 3 months of life, there were no statistically significant differences in the expression of MHC class II molecule between foal and adult horse macrophages (2.6 times, $p = 0.31$) and dendritic cells (1.3 times, $p = 0.37$). The percentage of MHC class II positive cells remained somewhat constant through age. CpG-ODN or LPS treatment did not promote specific changes in MHC class II expression in macrophages or DCs, yet a statistically significant difference in MHC class II expression was observed in stimulated cells in an age-dependent manner. The expression of the CD86 co-stimulatory molecule was comparable in adult horse and foal macrophages and DCs, independent of treatment.

Cytokine mRNA expression in stimulated and non-stimulated cells

Adult horse DCs increased the median IL-12p40 and IFN α mRNA expression 53 and 23 times, respectively, upon CpG-ODN stimulation, in comparison to non-stimulated DCs ($p = 0.078$). Adult horse CpG-ODN-stimulated macrophages did not change their cytokine mRNA expression in comparison to non-stimulated cells (Figure 4). Foal APCs did not change mRNA cytokine expression in an age-dependent manner upon CpG-ODN stimulation up to 3 months of age; instead, random fold differences were observed in the data with both CpG-ODN and LPS stimulation (Figures 5 and 6). The expression of IL-12p40 and IFN α in adult horse non-stimulated DCs were comparable to foal DCs at birth ($p > 0.05$). Despite the distinct median values, there was not a statistically significant difference in CpG-ODN stimulated cells between both groups. In order to evaluate if LPS was inducing a different pattern of cytokine expression than CpG-ODN, we tested TNF α mRNA expression in a small subset of adult horse samples: at 14–16 hours, CpG-ODN-stimulated DCs revealed a 5-fold increase in comparison to non-stimulated DCs, whereas LPS-stimulated-DCs revealed a 1-fold decrease. Stimulated and non-stimulated macrophages did not show any differences in their TNF α mRNA expression.

TLR9 and NF- κ B signaling pathway

TLR-9 mRNA expression in foal DCs and macrophages were comparable ($p > 0.05$) to adult horse cells, and CpG-ODN treatment induced upregulation of a 1-fold difference in comparison to non-stimulated and LPS-stimulated cells (Figure 7). Values for NF- κ B activation (NF- κ B




Figure 1

Equine monocyte-derived macrophages (A) and dendritic cells (B) generated *ex vivo*. Isolated peripheral blood monocytes were stimulated (dendritic cells) or not (macrophages) with rEq IL-4 and rHuGM-CSF in DMEM-F12, 5% bovine growth serum. The photomicrographs depict the differentiation of adult horse and foal macrophages and dendritic cells in culture. A and B = day 5 adult horse and foal macrophages, respectively; A' and B' = day 5 adult horse and foal dendritic cells, respectively – note their extended shape in contrast to the round macrophages; C = day 6 dendritic cells adhered to the plastic of the cell culture plate; C' = a group of day 6 dendritic cells floating in the supernatant of the cell culture – note the presence of small dendrites. Bars indicate 50 μm .

p65) were comparable ($p < 0.05$) in adult horse and foal macrophages and DCs, independent of treatment.

Discussion

Age-dependent aspects of APCs in the horse

Limitations in the immune system of the foal could be associated with age-dependent development of cell interaction for a primary immune response. The low expression of MHC class II in equine neonate and young foal peripheral blood lymphocytes has been well documented, but the expression of this essential molecule in APCs had not been studied before in the foal [34,35]. Our investigation revealed 2 important observations: a) there was a statistically significant difference in the fluorescence expression of MHC class II in macrophages and DCs of foals with age; and b) median MHC class II fluorescence expression in non-stimulated macrophages and DCs of the foal at birth were 12.5 times and 11.2 times inferior, respectively, to adult horse cells. The median MHC class II fluorescence expression in non-stimulated DCs of 3 month-old-foals was comparable to adult horses, which

suggests a greater competence for the priming of T cells at that age. In human fetuses, the percentage of MHC class II-positive monocytes increases significantly over gestation but remains lower than the adult human at term [36]. Limitation in APC number and function in young age has been shown to contribute to poor protective cellular immune responses [37-39]. Human cord blood DCs are less efficient in the activation of T cells *in vitro* and instruction to a Type 1 immune response, likely due to their lower cell surface MHC class I and II, co-stimulatory (CD86), and adhesion molecule expression levels than adult human blood cells [40].

Likewise, the expression of cytokines and co-stimulatory molecules (signal II) in APCs had not been studied before in foals. These important immune mediators are critical for the priming and clone expansion of naïve T cells. There were no statistically significant differences in the expression of CD86 in foal macrophages and DCs. In addition, there were no age-dependent changes in the expression of CD86. Importantly, those values were comparable to the

MACROPHAGE AND DENDRITIC CELL CELL SURFACE MARKERS




Figure 2

Percentage positive cells (%) and mean fluorescence intensity (MFI) of cell surface molecule expression in monocyte-derived macrophages (MO) and dendritic cells (DC) cultured for 5 days *ex vivo*. Note that immature dendritic cells revealed greater molecular expression (fluorescence intensity) for MHC class II and CD86 than macrophages, and inferior percentage of CD14-positive cells.

adult horse, and they suggest that APCs of foals are competent in the expression of the CD86 co-stimulatory molecule.


Response to stimulus

CpG-ODN 2135 was a functional tool to evaluate the innate immune response in foals, and to compare those results to adult horse response. We learned that adult horse DCs, but not macrophages, increased the IL-12p40 and IFN α mRNA expression 53 and 23 times, respectively, in comparison to non-stimulated DCs, whereas foal DCs did not respond specifically to that stimulus up to 3 months of life. Despite the lack of statistical difference, the contrast between foal and adult horse cell cytokine responses to CpG-ODN should not be overlooked, but further pursued for better understanding of foal response to different types of pathogens and vaccines/adjuvants. Other CpG-ODN motifs could induce different types and magnitude of response by adult horse and foal cells. However, the CpG-ODN motif used herein revealed a difference between adult horse and foal DC response. Indeed,

in our pilot studies, this same CpG-ODN induced greater proliferation indexes in adult horse peripheral blood leukocytes than foal cells.

Interleukin-12 is a heterodimeric molecule composed of p35 and p40 subunits. Upon CpG-ODN stimulation, adult horse DCs increased the expression of IL-12p40, which was not matched in magnitude by IL-12p35. Holscher et al. [41] demonstrated a protective and agonistic role of IL-12p40 in mycobacterial infection in IL-12p35 knockout mouse. This immune effect could have been associated with the expression of IL-23, which comprises the same p40 subunit of IL-12 but a different p19 subunit. Therefore, it is possible that the IL-12p40 response to CpG-ODN in adult horse DCs may reflect the expression of IL-23, instead, and that needs to be tested. Whereas IL-12 promotes the development of naïve T cells, IL-23 participates in the activation of memory T cells and chronic inflammation, and this difference is relevant when studying the development of primary immune response in foals [42].

ADULT HORSES



FOALS




Figure 3

Mean fluorescence intensity (MFI) of cell surface molecule expression in monocyte-derived macrophages and dendritic cells stimulated with CpG-ODN for 14–16 hours after 5 days of culture *ex vivo*. Results are depicted for adult horses (A, n = 7) and foals (B, n = 7) of different ages. Although there was no specific effect of CpG-ODN or LPS stimulation in adult horse or foal cells, there was an age-dependent limitation in the expression of MHC class II on macrophage and dendritic cells of foals. The median fluorescence of the MHC class II molecule in non-stimulated foal macrophages and DCs at birth were 12.5× (p = 0.009) and 11.2× (p = 0.009) inferior, respectively, than adult horse cells, and 2.6× (p = 0.31) and 1.3× (p = 0.37), respectively, at 3 months of life.




Figure 4
 Quantitative cytokine (IL-12p35, IL-12p40, IFN α , IL-10) mRNA expression in adult horse (n = 7) monocyte-derived macrophages and dendritic cells stimulated or not (NoStim) with CpG-ODN or LPS for 14–16 hours after 5 days of culture ex vivo. Fold difference was calculated using baseline control values (non-stimulated cells on Day 5).




Figure 5
 Quantitative cytokine (IL-12p35 and IL-12p40) mRNA expression in foal (n = 7; A = birth, B = 1 month, C = 2 months, D = 3 months) monocyte-derived macrophages and dendritic cells stimulated or not (NoStim) with CpG-ODN or LPS for 14–16 hours after 5 days of culture ex vivo. Fold difference was calculated using baseline control values (non-stimulated cells on Day 5).




Figure 6
 Quantitative cytokine (IFN α and IL-10) mRNA expression in foal (n = 7; A = birth, B = 1 month, C = 2 months, D = 3 months) monocyte-derived macrophages and dendritic cells stimulated or not (NoStim) with CpG-ODN or LPS for 14–16 hours after 5 days of culture ex vivo. Fold difference was calculated using baseline control values (non-stimulated cells on Day 5).

Both IL-12 and IFN α promote activation of T cells into Type 1 immune response, with activation, proliferation and IFN γ production [43,44]. Subsequently, CD40-ligand

engagement and IFN γ from activated T cells facilitate the production of IL-12 by APCs [45,46]. Indeed, mouse conventional DCs require IFN γ co-stimulation for the produc-




Figure 7
 Quantitative analysis of TLR9 and NFkB p65 in monocyte-derived macrophages and dendritic cells stimulated with CpG-ODN or LPS for 14–16 hours after 5 days of culture ex vivo. Results are depicted for (A) adult horses (n = 7) and (B) foals of different ages (n = 7; A = birth, B = 1 month, C = 2 months, D = 3 months).

tion of the active form of IL-12 upon TLR stimulation [47]. Therefore, an impaired cytokine signaling for appropriate APC activation in foals could not only hamper a subsequent Type 1 primary immune response, but also the proper activation of APCs. In fact, this may be a limiting factor in foals because Breathnach et al. [48] have demonstrated that the equine neonate peripheral blood and pulmonary lymphocytes present a marked low response for the production of IFN γ , which improves steadily with age.

Compromised Th1 differentiation has been also observed when there is CD4+ T cell hyporesponsiveness to IL-12 [49]. In young age, DC maturation and cytokine production may require specific and co-stimulatory stimuli, which may become less crucial in a more developed (adult) immune system. In addition, IL-12 production can be antagonized by the presence of the anti-inflammatory cytokines IL-10 and TGF β [50]. Foal DCs did not alter the expression of IL-12 upon stimulation; yet, those cells did not change the expression of IL-10 either. Therefore, it is unlikely the lack of IL-12 response was due to a bias of the foal cells toward an anti-inflammatory state; rather, it is possible that those cells have a decreased overall response to stimulus up to 3 months of life through the TLR9 signaling pathway [51].

Similarly to CpG-ODN, LPS has been shown to induce DC maturation with cytokine production, up-regulation of co-stimulatory molecules and activation of T cells. Those effects were not observed in our data. LPS inflammatory stimulation involves both common and different pathways to CpG-ODN, and distinct cytokine expression kinetics has been observed [17,52]. To investigate whether LPS was inducing a different pattern of cytokine response, we evaluated the TNF α mRNA expression in a subset of adult horse samples. At 14–16 hours of stimulation, CpG-ODN- or LPS-stimulated DCs expressed TNF α mRNA with a median 5-fold increase and 1-fold decrease, respectively, in comparison to non-stimulated cells. It is possible that the peaks of cytokine expression of LPS-stimulated DCs were missed by the time the cells were harvested, and measuring protein levels would have been a better comparison.

Two classes of CpG have been described to induce different effects in human cells: CpG-A and CpG-B. The former has a phosphodiester core with CpG motifs, flanked by phosphorothioate poly(G) sequences on both the 3' and 5' ends; the latter is mainly a phosphorothioate, nuclease resistant backbone [53,54]. CpG-A had been originally known to stimulate plasmacytoid DCs to express large amounts of IFN α ; and CpG-B as a potent stimulator of B cell proliferation and secretion of IL-10 [1,3,55,56]. Both types of CpG require TLR9 for immune stimulation [57].

However, only CpG-B has been shown to activate NF-kB, whereas CpG-A induces a minimal response [58]. In our studies, median TLR9 expression was comparable in CpG-ODN-treated or LPS-treated macrophages and DCs of foal and adult horse cells. NF-kB activation in foal macrophages and DCs was comparable to adult horse cells, and CpG-ODN or LPS treatment did not reveal an effect in any of the groups. Therefore, those analyses were not informative of the mechanisms involved in cell activation upon CpG-ODN stimulation.

Structurally, the CpG-ODN used in these experiments is of class B. However, its effect on horse cells resembled the one of class A in other species for the increased IFN α expression and lack of concomitant increased expression of NF-kB in the adult horse dendritic cells. Distinct responses to CpG-ODN have been described in different species. Mena et al. [59] have shown a specific and dose-dependent IFN α response to class B CpG-ODN motif-stimulated ovine, but not bovine, peripheral blood mononuclear cells. In addition, class B CpG-ODN has been shown to induce *in vitro* IFN α production in newborn lambs, which seems to contrast with our findings in foals [60]. Nevertheless, it is possible that IFN α expression in equine cells is higher when cells are stimulated with class A CpG-ODN. Watrang et al. [19] demonstrated that class A CpG-ODN indeed induces IFN α expression by equine peripheral blood mononuclear cells.

The maturation of DCs measured by MHC class II expression upon CpG-ODN stimulus was not obvious in adult horse cells, potentially because those cells were already expressing high levels of that molecule on the cell surface on Day 5 of the *ex vivo* culture. Alternatively, there were mixed-maturation stage cells in the cell culture well, and only a fraction of those cells became mature with greater MHC class II expression. Our flow cytometric analysis for MHC class II expression did not include specific gated areas in the DC population to keep consistent with the mRNA cytokine data, which was generated from the whole cell population. Yet, a subpopulation of cells with high side and forward scatters in the dot plots expressed the highest levels of MHC class II, and CpG-ODN stimulation could have induced distinct increased expression of that molecule in comparison to controls.

Categorization of the monocyte-derived macrophages and dendritic cells

The *ex vivo* model presented here produced monocyte-derived macrophages and DCs with characteristics comparable to published results [26,33,61,62]. On Day 5 of cell culture, rEqIL-4 + rHuGM-CSF induced a slight increase in the expression of MHC class II molecule (fluorescence), whereas the number of cells (percentage) expressing CD14 molecule was decreased in comparison

to control. Those results suggest the generation of immature DCs, which were desired for our experiments. Nevertheless, it is unlikely that this system produced macrophage or DC cell populations in synchronous stages of development. Both macrophages and DCs were derived primarily from adherent peripheral blood mononuclear cells, and a high percentage of cells expressing the CD172a molecule was present in the cell culture. Although CpG-ODN may not have induced DC maturation per se as it is classically measured (i.e. increased MHC class II expression), only stimulated DCs (and not non-stimulated DCs and stimulated macrophages) induced IL-12p40 and IFN α cytokine expression.

The classification of DCs is quite complex: the heterogeneity of DCs is determined by the precursor population, anatomical localization, function, and the final outcome of the immune response [15,63]. Several DC subsets have been identified in human and mouse, and some similarities and differences exist between species [64]. Two major categories, conventional DCs or plasmacytoid DCs, can be described according to the cell origin, TLR expression and cytokine profile. The cell surface marker CD11c has been an important parameter in the identification of DCs; however a monoclonal antibody that recognizes this marker is lacking for the equine species. In general, conventional DCs express TLR4 and plasmacytoid DCs express TLR9, and other TLRs may or not be expressed in the same cell types in both species [65]. In addition, conventional DCs are known to produce high levels of IL-12, whereas plasmacytoid DCs produce type I IFN (IFN α) and IL-12 [16].

To date, there is no single reliable method for the characterization and categorization of equine DCs derived from peripheral blood or from peripheral or lymphoid tissues. Therefore, the combination of cell surface marker expression, using the monoclonal antibodies available for the horse species, and the expression of cytokines upon stimulation may reveal preliminary characteristics of those cells. It is not clear from our analyses if the cells producing IFN α and IL-12 were positive or not for the CD172a and CD14 markers. This question would require a double staining of cytokines and cell surface markers, and those reagents are not widely available for horse proteins to this date. Alternatively, this system generates a type of DC that does not follow a predetermined classification system, such as the one described by Asselin-Paturel et al. [66], a unique subset of murine immature APCs with plasmacytoid morphology that secrete IFN α and IL-12 upon stimulation with viruses and CpG-ODN.

Conclusion

The results from our *ex vivo* system suggest that foal APCs do not respond to stimulus comparably to adult horse cells in cytokine expression. In addition, this investigation

revealed an age-dependent limitation in the expression of MHC class II molecule in the APCs of the newborn and young foal, although the expression of the co-stimulatory molecule CD86 seems to be present already in early life. Our studies are not comprehensive in determining the intrinsic developmental aspects of the foal APCs, yet they bring new observations to support future studies in the competence of the foal cells to elicit a primary immune response, and in the choice of appropriate adjuvants for use in young age. CpG-ODN has shown positive effects in DC maturation and activation in neonatal cells of other species. In addition, different CpG-ODN motifs have distinct effect in immune cells. Other types of stimulants (e.g. inactivated whole Gram positive or negative organisms, inactivated viruses, or distinct CpG-ODN motifs) may further indicate levels of response, and potential limitations of APCs to signal T cells for a primary immune response in young age.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

MJBFF conceived the study design, coordinated the study, performed the blood collection, and flow cytometric analysis. MBM performed the cell culture, cell harvesting and freezing. ASB performed the RNA isolation, real-time quantitative RT-PCR, and chemiluminescence assay. DWH provided technical orientation and reagents for the cell culture. RH determined and provided the motif to be used in the experiments. MJBFF and ASB prepared the draft of the manuscript. DVN and ASB performed the data analysis. All authors read and contributed to the final version of the manuscript.

Acknowledgements

The authors would like to thank Carol Collyer and staff at the Cornell University Equine Park for facilitating the handling of the foals. We are also grateful to Dr. Philip J. Griebel from the Veterinary Infectious Disease Organization (VIDO), Saskatchewan, Canada for his insightful comments and suggestions. This study was supported by the Harry M. Zweig Memorial Fund for Equine Research and CAPES-Brazil Fellowship (A.S.Borges).

References

1. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: **CpG motifs in bacterial DNA trigger direct B-cell activation.** *Nature* 1995, **374**:546-549.
2. Tokunaga T, Yamamoto T, Yamamoto S: **How BCG led to the discovery of immunostimulatory DNA.** *Jpn J Infect Dis* 1999, **52**:1-11.
3. Krieg AM: **CpG motifs in bacterial DNA and their immune effects.** *Annu Rev Immunol* 2002, **20**:709-760.
4. Maletto B, Ropolo A, Moron V, Pistoresi-Palencia MC: **CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/c mice.** *J Leukoc Biol* 2002, **72**:447-454.
5. Gramzinski RA, Doolan DL, Sedegah M, Davis HL, Krieg AM, Hoffman SL: **Interleukin-12- and gamma-interferon-dependent pro-**

- tection against malaria conferred by CpG oligodeoxynucleotide in mice. *Infect Immun* 2001, **69**:1643-1649.
6. Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, Turon TN, Davey DF, Davis H, Klinman DM, Coler RN, Sacks DL, Seder RA: **Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania infection.** *J Exp Med* 2002, **195**:1565-1573.
 7. Mutwiri G, Pontarollo R, Babiuk S, Griebel P, van Drunen Littel-van den Hurk S, Mena A, Tsang C, Alcon V, Nichani A, Ioannou X, Gomis S, Townsend H, Hecker R, Potter A, Babiuk LA: **Biological activity of immunostimulatory CpG DNA motifs in domestic animals.** *Vet Immunol Immunopathol* 2003, **91**:89-103.
 8. Vecchione A, Catchpole B, D'Mello F, Kanellos T, Hamblin A: **Modulating immune responses with dendritic cells: an attainable goal in veterinary medicine?** *Vet Immunol Immunopathol* 2002, **87**:215-221.
 9. Klinman DM: **CpG Adjuvant activity of CpG oligodeoxynucleotides.** *Int Rev Immunol* 2006, **25**:135-154.
 10. Ioannou XP, Griebel P, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S: **The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides.** *J Virol* 2002, **76**:9002-9010.
 11. Dory D, Beven V, Torche AM, Bougeard S, Cariolet R, Jestin A: **CpG motif in ATCGAT hexamer improves DNA-vaccine efficiency against lethal Pseudorabies virus infection in pigs.** *Vaccine* 2005, **23**:4532-4540.
 12. Lopez AM, Hecker R, Mutwiri G, van Drunen Littel-van den Hurk S, Babiuk LA, Townsend HG: **Formulation with CpG ODN enhances antibody responses to an equine influenza virus vaccine.** *Vet Immunol Immunopathol* 2006, **114**:103-110.
 13. Aderem A, Ulevitch RJ: **Toll-like receptors in the induction of the innate immune response.** *Nature* 2000, **406**:782-787.
 14. Akira S, Takeda K: **Toll-like receptor signaling.** *Nat Rev Immunol* 2004, **4**:449-511.
 15. Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J, Palucka AK: **Dendritic cells: controllers of the immune system and a new promise for immunotherapy.** *Ann N Y Acad Sci* 2003, **987**:180-187.
 16. Cella M, Facchetti F, Lanzavecchia A, Colonna M: **Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization.** *Nat Immunol* 2000, **1**:305-310.
 17. Hartmann G, Weiner GJ, Krieg AM: **CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells.** *Proc Natl Acad Sci USA* 1999, **96**:9305-9310.
 18. Askew D, Chu RS, Krieg AM, Harding CV: **CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms.** *J Immunol* 2000, **165**:6889-6895.
 19. Watrang E, Berg M, Magnusson M: **Immunostimulatory DNA activates production of type I interferons and interleukin-6 in equine peripheral blood mononuclear cells in vitro.** *Vet Immunol Immunopathol* 2005, **107**:265-279.
 20. Krutzik SR, Tan B, Li H, Ochoa MT, Liu PT, Sharfstein SE, Graeber TG, Sieling PA, Liu YJ, Rea TH, Bloom BR, Modlin RL: **TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells.** *Nat Med* 2005, **11**:653-660.
 21. Levy O, Zarembek KA, Roy RM, Cywes C, Godowski PJ, Wessels MR: **Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848.** *J Immunol* 2004, **173**:4627-4634.
 22. Levy O: **Innate immunity of the human newborn: distinct cytokine responses to LPS and other Toll-like receptor agonists.** *J Endotoxin Res* 2005, **1192**:113-116.
 23. Nichani AK, Mena A, Kaushik RS, Mutwiri GK, Townsend HG, Hecker R, Krieg AM, Babiuk LA, Griebel P: **Stimulation of innate immune responses by CpG oligodeoxynucleotide in newborn lambs can reduce bovine herpesvirus-1 shedding.** *Oligonucleotides* 2006, **16**:58-67.
 24. Hines SA, Stone D, Hines MT, Alperin DC, Knowles DP, Norton L, Hamilton MJ, Davis WC, McGuire TC: **Clearance of virulent but not avirulent Rhodococcus equi from the lungs of adult horses is associated with intracytoplasmic gamma interferon production by CD4+ and CD8+ T lymphocytes.** *Clin Diagn Lab Immunol* 2003, **10**:208-215.
 25. Hooper-McGrevey KE, Wilkie BN, Prescott JF: **Immunoglobulin G Subisotype Responses of Pneumonic and Healthy, Exposed Foals and Adult Horses to Rhodococcus equi Virulence-Associated Proteins.** *Clin Diagn Lab Immunol* 2003, **10**:345-51.
 26. Hammond SA, Horohov D, Montelaro RC: **Functional characterization of equine dendritic cells propagated ex vivo using recombinant human GM-CSF and recombinant IL-4.** *Vet Immunol Immunopathol* 1999, **71**:197-214.
 27. Rankin R, Pontarollo R, Ioannou X, Krieg AM, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S: **CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved.** *Antisense Nuc Acid Drug Develop* 2001, **11**:333-340.
 28. Flaminio MJBF, LaCombe V, Kohn CW, Antczak DF: **Common variable immunodeficiency in a mare.** *J Am Vet Med Assoc* 2002, **221**:1296-1302.
 29. Kydd J, Antczak DF, Allen WR, Barbis D, Butcher G, Davis W, Duffus WPH, Edington N, Grunig G, Holmes MA, Lunn DP, McCulloch J, O'Brien A, Perryman LE, Tavernor A, Williamson S, Zhang C: **Report of the First International Workshop on Equine Leukocyte Antigens, Cambridge, UK.** *Vet Immunol Immunopathol* 1994, **42**:3-60.
 30. Lunn DP, Holmes MA, Antczak DF, Agerwal N, Baker J, Bendali-Ahcene S, Blanchard-Channell M, Byrne KM, Cannizzo K, Davis W, Hamilton MJ, Hannant D, Kondo T, Kydd JH, Monier MC, Moore PF, O'Neil TO, Schram BR, Sheoran A, Stott JL, Sugiura T, Vagnoni KE: **Report of the Second Equine Leukocyte Antigen Workshop, Squaw Valley, California, July 1995.** *Vet Immunol Immunopathol* 1998, **62**:101-143.
 31. Parrish CR, Carmichael LE, Antczak DF: **Antigenic relationships between canine parvovirus Type-2, feline panleukopenia virus and mink enteritis virus using conventional antisera and monoclonal antibodies.** *Arch Virol* 1982, **72**:267-278.
 32. Flaminio MJBF, Antczak DF: **Inhibition of lymphocyte proliferation and activation: a mechanism used by equine invasive trophoblast to escape the maternal immune response.** *Placenta* 2005, **26**:148-159.
 33. Muel S, Steinbach F, Ludwig H: **Monocyte-derived dendritic cells from horses differ from dendritic cells of humans and mice.** *Immunology* 2006, **117**:463-473.
 34. Lunn DP, Holmes MA, Duffus WVP: **Equine T-lymphocyte MHC II expression: variation with age and subset.** *Vet Immunol Immunopathol* 1993, **35**:225-238.
 35. Flaminio MJ, Rush BR, Davis EG, Hennessy K, Shuman W, Wilkerson MJ: **Characterization of peripheral blood and pulmonary leukocyte function in healthy foals.** *Vet Immun Immunopathol* 2000, **73**:267-285.
 36. Jones CA, Holloway JA, Warner JO: **Phenotype of fetal monocytes and B lymphocytes during the third trimester of pregnancy.** *J Reprod Immunol* 2002, **56**:45-60.
 37. Petty RE, Hunt DW: **Neonatal dendritic cells.** *Vaccine* 1998, **16**:1378-1382.
 38. Muthukkumar S, Goldstein J, Stein KE: **The ability of B cells and dendritic cells to present antigen increases during ontogeny.** *J Immunol* 2000, **165**:4803-4813.
 39. Pihlgren M, Tougne C, Bozzotti P, Fulurija A, Duchosal MA, Lambert PH, Siegrist CA: **Unresponsiveness to lymphoid-mediated signals at the neonatal follicular dendritic cell precursor level contributes to delayed germinal center induction and limitations of neonatal antibody responses to T-dependent antigens.** *J Immunol* 2003, **170**:2824-2832.
 40. Hunt DW, Huppertz HI, Jiang HJ, Petty RE: **Studies of human cord blood dendritic cells: evidence for functional immaturity.** *Blood* 1994, **84**:4333-4343.
 41. Holscher C, Atkinson RA, Arendse B, Brown N, Myburgh E, Alber G, Brombacher F: **A protective and agonistic function of IL-12p40 in mycobacterial infection.** *J Immunol* 2001, **167**:6957-6966.
 42. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD: **Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.** *Nature* 2003, **421**:744-748.

43. Magram J, Connaughton SE, Warriar RR, Carvajal DM, Wu CY, Ferrante J, Stewart C, Sarmiento U, Faherty DA, Gately MK: **IL-12-deficient mouse are defective in IFN gamma production and type I cytokine responses.** *Immunity* 1996, **4**:471-481.
44. Le Bon A, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, Rossmann C, Kalinke U, Tough DF: **Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming.** *J Immunol* 2006, **176**:4682-4689.
45. Schulz O, Edwards AD, Schito M, Aliberti J, Manickasingham S, Sher A, Reis e Sousa C: **CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal.** *Immunity* 2000, **13**:453-462.
46. Belardelli F: **Role of interferons and other cytokines in the regulation of the immune response.** *APMIS* 1995, **103**:161-179.
47. Hayes MP, Wang J, Norcross MA: **Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes.** *Blood* 1995, **86**:646-650.
48. Breathnach CC, Sturgill-Wright T, Stiltner JL, Adams AA, Lunn DP, Horohov DW: **Foals are interferon gamma-deficient at birth.** *Vet Immunol Immunopathol* 2006, **112**:199-209.
49. Taki S, Sato T, Ogasawara K, Fukuda T, Sato M, Hida S, Suzuki G, Mitsuyama M, Shin EH, Kojima S, Taniguchi T, Asano Y: **Multistage regulation of Th1-type immune responses by the transcription factor IRF-1.** *Immunity* 1997, **6**:673-679.
50. Ma X, Trinchieri G: **Regulation of interleukin-12 production in antigen-presenting cells.** *Adv Immunol* 2001, **79**:55-92.
51. Langrish CL, Buddle JC, Thrasher AJ, Goldblatt D: **Neonatal dendritic cells are intrinsically biased against Th-1 immune responses.** *Clin Exp Immunol* 2002, **128**:118-123.
52. Kaisho T, Akira S: **Pleiotropic function of Toll-like receptors.** *Microbes Infect* 2004, **6**:1388-1394.
53. Dalpke AH, Zimmermann S, Albrecht I, Heeg K: **Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo.** *Immunology* 2002, **106**:102-112.
54. Hemmi H, Kaisho T, Takeda K, Akira S: **The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets.** *J Immunol* 2003, **170**:3059-3064.
55. Lipford GB, Bendigs S, Heeg K, Wagner H: **Poly-guanosine motifs costimulate antigen-reactive CD8 T cells while bacterial CpG-DNA affect T-cell activation via antigen-presenting cell-derived cytokines.** *Immunology* 2000, **101**:46-52.
56. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G: **Identification of CpG oligodeoxynucleotide sequences with high induction of IFN α /b in plasmacytoid dendritic cells.** *Eur J Immunol* 2001, **31**:2154-2163.
57. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G: **Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.** *J Immunol* 2002, **168**:4531-4537.
58. Klinman DM, Takeshita F, Gursel I, Leifer C, Ishii KJ, Verthelyi D, Gursel M: **CpG DNA: recognition by and activation of monocytes.** *Microbes Infect* 2002, **4**:897-901.
59. Mena A, Nichani AK, Popowych Y, Ioannou XP, Godson DL, Mutwiri GK, Hecker R, Babiuk LA, Griebel PJ: **Bovine and ovine blood mononuclear leukocytes differ markedly in innate immune responses induced by Class A and Class B CpG-oligodeoxynucleotide.** *Oligonucleotides* 2003, **13**:245-259.
60. Nichani AK, Mena A, Kaushik RS, Mutwiri GK, Townsend HG, Hecker R, Babiuk LA, Griebel PJ: **Stimulation of innate immune responses by CpG oligodeoxynucleotide in newborn lambs can reduce bovine herpesvirus-1 shedding.** *Oligonucleotides* 2006, **16**:58-67.
61. Siedek E, Little S, Mayall S, Edington N, Humblin A: **Isolation and characterization of equine dendritic cells.** *Vet Immunol Immunopathol* 1997, **60**:15-31.
62. Steinbach F, Krause B, Blass S, Burmester GR, Hiepe F: **Development of accessory phenotype and function during differentiation of monocyte-derived dendritic cells.** *Res Immunol* 1998, **149**:627-632.
63. Bajer AA, Garcia-Tapia D, Jordan KR, Haas KM, Werling D, Howard CJ, Estes DM: **Peripheral blood-derived bovine dendritic cells promote IgG1-restricted B cell responses in vitro.** *J Leukoc Biol* 2003, **73**:100-106.
64. Hemmi H, Akira S: **TLR signaling and the function of dendritic cells.** *Chem Immunol Allergy* 2005, **86**:120-135.
65. Akira S, Hemmi H: **Recognition of pathogen-associated molecular patterns by TLR family.** *Immunol Lett* 2003, **85**:85-95.
66. Asselin-Paturel C, Boonstra A, Dalod M, Durand I, Yessaad N, Dezutter-Dambuyant C, Vicari A, O'Garra A, Biron C, Briere F, Trinchieri G: **Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology.** *Nat Immunol* 2001, **2**:1144-1150.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

